Background: Tissue factor (TF) expression by tumors contributes to tumor growth. Release of
TF‐positive microparticles (MPs) may contribute to venous thromboembolism (VTE) …

Cancer patients exhibit a high rate of thromboembolism (VTE). In this study, we analyzed
levels of microparticle (MP) tissue factor (TF) activity in cancer patients with or without VTE …

Background: Cancer, in particular mucinous adenocarcinoma, is associated with venous
thromboembolism (VTE). Tissue factor (TF), initiator of coagulation, plays a central role in the …

In a previous study [1], we found that the tissue factor (TF) activity of microparticles (MP)
isolated from platelet-poor plasma (MP-TF activity) was markedly increased in patients with …

Background Tissue factor (TF), the physiologic initiator of coagulation, is over-expressed in
pancreatic cancer, and is associated with a pro-coagulant and pro-angiogenic state. We …

Patients with cancer have an increased risk for venous thrombosis. Interestingly, different
cancer types have different rates of thrombosis, with pancreatic cancer having one of the …

Pancreatic cancer is the fourth leading cause of cancer death in the US [1]. It is frequently
complicated by venous thromboembolism (VTE), with published incidence rates varying …

Cancer is associated with an increased risk of venous thromboembolism (VTE); the exact
mechanisms for the induction of VTE remain to be fully elucidated, but it is widely …

Purpose: Despite the strong association between malignant disease and thromboembolic
disorders, the molecular and cellular basis of this relationship remains uncertain. We …

The pathogenesis of hypercoagulability in cancer is not entirely understood. We
hypothesized that in cancer patients circulating tissue factor-positive microparticles (TF+ …